| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Not Yet Recruiting | Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese NCT06674837 | ANRS, Emerging Infectious Diseases | — |
| Active Not Recruiting | Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence Areas NCT06678373 | Liaoning Chengda Biotechnology CO., LTD | Phase 4 |
| Completed | Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) NCT06331702 | Liaoning Chengda Biotechnology CO., LTD | Phase 4 |
| Completed | Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary Immunization NCT06372665 | Liaoning Chengda Biotechnology CO., LTD | — |
| Unknown | An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity NCT05568953 | Singapore General Hospital | Phase 2 |
| Completed | Flavivirus Cross-priming Potential of IMOJEV NCT03920111 | University of Liverpool | N/A |
| Unknown | Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With NCT04817917 | Zhejiang Provincial Center for Disease Control and Prevention | Phase 4 |
| Completed | Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam NCT03282370 | National Institute of Hygiene and Epidemiology, Vietnam | Phase 3 |
| Completed | Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months NCT03204227 | National Institute of Hygiene and Epidemiology, Vietnam | Phase 2 |
| Completed | Postmarketing Surveillance Study for IMOJEV® in Republic of Korea NCT02933710 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines NCT02643433 | Centers for Disease Control and Prevention, China | Phase 4 |
| Completed | Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vac NCT02532569 | Boryung Pharmaceutical Co., Ltd | Phase 4 |
| Completed | Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healt NCT02492165 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity of JECEVAX in Young Children NCT02816554 | National Institute of Hygiene and Epidemiology, Vietnam | Phase 2 |
| Completed | Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine NCT02602652 | Chulalongkorn University | N/A |
| Completed | Post-licensure Safety Study of IMOJEV® in Thailand NCT01981967 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Unknown | Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children NCT01954810 | Khon Kaen University | Phase 4 |
| Completed | Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea NCT01900444 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine NCT01815073 | Changchun Keygen Biological Products Co., Ltd. | Phase 4 |
| Completed | Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in NCT01662440 | Novartis Vaccines | Phase 3 |
| Withdrawn | Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination NCT01559831 | Valneva Austria GmbH | Phase 1 |
| Completed | A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA1 NCT01656200 | Indian Institute of Science | Phase 4 |
| Completed | Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine NCT01567865 | PATH | Phase 4 |
| Completed | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines W NCT01466387 | Novartis | Phase 3 |
| Completed | Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Tod NCT01396512 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety Surveillance After Immunization With IXIARO NCT01335412 | Valneva Austria GmbH | — |
| Completed | Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country NCT01296360 | Valneva Austria GmbH | Phase 3 |
| Completed | Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Populat NCT01246479 | Valneva Austria GmbH | Phase 3 |
| Completed | Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV NCT01190228 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea NCT01150942 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese To NCT01188343 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population NCT01158599 | Valneva Austria GmbH | Phase 4 |
| Unknown | Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan NCT01163123 | Mennonite Christian Hospital | — |
| Completed | A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddler NCT01092507 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) NCT01001988 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR NCT00938379 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis NCT01856205 | University of Liverpool | Phase 2 |
| Completed | Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling NCT00776230 | Valneva Austria GmbH | Phase 3 |
| Completed | Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines NCT00735644 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children NCT00621764 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis NCT01386827 | Helsinki University Central Hospital | Phase 3 |
| Completed | Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 NCT00595465 | Valneva Austria GmbH | Phase 3 |
| Completed | Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 NCT00595309 | Valneva Austria GmbH | Phase 3 |
| Completed | Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received NCT00463476 | PATH | Phase 4 |
| Completed | Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of NCT00463684 | PATH | Phase 4 |
| Completed | Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending A NCT00441259 | Sanofi | Phase 2 |
| Completed | Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 NCT00594958 | Valneva Austria GmbH | Phase 3 |
| Completed | A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX NCT00314145 | Sanofi | Phase 3 |
| Completed | Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 NCT00595270 | Valneva Austria GmbH | Phase 3 |
| Completed | Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. NCT00314132 | Sanofi | Phase 3 |
| Completed | Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 NCT00596102 | Valneva Austria GmbH | — |
| Completed | Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 NCT00605085 | Valneva Austria GmbH | Phase 3 |
| Completed | Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 NCT00604708 | Valneva Austria GmbH | Phase 3 |
| Completed | Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 NCT00596271 | Valneva Austria GmbH | Phase 3 |
| Completed | Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 NCT00595790 | Valneva Austria GmbH | Phase 3 |
| Unknown | Treatment of Japanese Encephalitis NCT00216268 | Indian Council of Medical Research | Phase 2 |
| Completed | A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX NCT00319592 | Sanofi | Phase 2 |
| Completed | Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine NCT00981630 | Sanofi | Phase 2 |
| Completed | Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) NCT00982137 | Sanofi | Phase 2 |
| Completed | A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults NCT00981175 | Sanofi | Phase 2 |
| Completed | Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With J NCT00694460 | Novartis | Phase 2 |